Ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacilli in an intensive care unit without carbapenemase-producing Enterobacteriaceae or epidemic Acinetobacter baumannii

Scandinavian Journal of Infectious Diseases

Volumn 46, Issue 3, 2014, Pages 215-220

  Soubirou, Jean François ^a   Gault, Nathalie ^a,b   Alfaiate, Toni ^a   Lolom, Isabelle ^a   Tubach, Florence ^a,b   Andremont, Antoine ^a   Lucet, Jean Christophe ^a   Wolff, Michel ^a   Barbier, François ^a  

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Carbapenem resistance; Extended spectrum lactamase; Healthcare associated infections; Pseudomonas aeruginosa; Stenotrophomonas maltophilia

Indexed keywords

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIA; CROSS INFECTION; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84894355438     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2013.871644     Document Type: Article

References (24)

1. Cohen J. Confronting the threat of multidrug-resistant Gram-negative bacteria in critically ill patients. J Antimicrob Chemother 2013;68:490-1.
2. Barbier F, Andremont A, Wolff M, Bouadma L. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 2013;19:216-28.
3. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe . Euro Surveill 2008;13:19045.
4. Timsit JF, Zahar JR, Chevret S. Attributable mortality of ventilator-associated pneumonia. Curr Opin Crit Care 2011;17:464-71.
5. Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 2013;13:665-71.
6. Agrafiotis M, Siempos II, Ntaidou TK, Falagas ME. Attributable mortality of ventilator-associated pneumonia: a meta-analysis. Int J Tuberc Lung Dis 2011;15:1154-63, i-v.
7. American Thoracic Society-Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
8. Torres A, Ewig S, Lode H, Carlet J. Defining, treating and preventing hospital-acquired pneumonia: European perspective. Intensive Care Med 2009;35:9-29.
9. RosenthalVD, Bijie H, Maki DG, MehtaY, Apisarnthanarak A, Medeiros EA, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009. Am J Infect Control 2012;40:396-407.
10. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010;51(Suppl 1):S81-7.
11. Rello J, Ulldemolins M, Lisboa T, Koulenti D, Manez R, Martin-Loeches I, et al. Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. Eur Respir J 2011;37: 1332-9.
12. Kollef MH, Golan Y, Micek ST, Shorr AF, Restrepo MI. Appraising contemporary strategies to combat multidrug resistant Gram-negative bacterial infections - proceedings and data from the Gram-Negative Resistance Summit. Clin Infect Dis 2011;53(Suppl 2):S33-55.
13. Nordmann P, Naas T, Poirel L. Global spread of carbapen-emase-producing Enterobacteriaceae. Emerg Infect Dis 2011;17:1791-8.
14. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 2012; 25:2-41.
15. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009;22:582-610.
16. Bowers DR, Liew YX, Lye DC, Kwa AL, Hsu LY, Tam VH. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2013;57:1270-4.
17. Vandenbroucke JP, Von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration]. Gac Sanit 2009;23:158.
18. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-9.
19. Armand-Lefevre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppe E, et al. Emergence of imipenem-resistant Gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 2013;57:1488-95.
20. Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol 2010;31:47-53.
21. Pena C, Guzman A, Suarez C, Dominquez MA, Tubau F, Pujol M, et al. Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients. Antimicrob Agents Chemother 2007;51:1967-71.
22. Lepelletier D, Cady A, Caroff N, Marraillac J, Reynaud A, Lucet JC, et al. Imipenem-resistant Pseudomonas aeruginosa gastrointestinal carriage among hospitalized patients: risk factors and resistance mechanisms. Diagn Microbiol Infect Dis 2010;66:1-6.
23. Vitkauskiene A, Dambrauskiene A, Cerniauskiene K, Rimdeika R, Sakalauskas R. Risk factors and outcomes in patients with carbapenem-resistant Acinetobacter infection. Scand J Infect Dis 2013;45:213-8.
24. Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C, Trouillet JL, et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004;38:670-7.